Full-Lifecycle Oral Solid Dosage and DPI CDMO solutions in Tampa, Florida

From concept through commercialization.

Our pharmaceutical CDMO delivers end-to-end oral solid dosage (OSD) and Dry Powder Inhalation (DPI) drug product services, from pre-formulation to cGMP released drug product. DEA Schedule I to V licensed. FDA inspected. Nine approved and six active commercial products manufactured for US and international markets.

 

9

Products approved from this site

6

Currently in active commercial manufacturing, US and international markets

5

Successful FDA inspections in the past 8 years

12

Successful regulatory audits in the past 8 years

DEA

Schedule I to V analytical and manufacturing licensed

 

 

Highlighted Capabilities

 

FOR EARLY-PHASE PROGRAMS

First-in-Human: Quick to Clinic

Deliver cGMP drug product to the clinic faster. 
Designed for early-phase programs that need speed without compromising quality or regulatory compliance.

  • Encapsulate drug substance directly into a capsule to create drug product
  • Xcelodose® Precision Powder Micro-dosing System
  • cGMP compliant for clinical trial supply
PROVEN COMMERCIAL TRACK RECORD

9 Approved Products. 6 on the Market Today.

Nine products have been approved for commercial for commercial manufacturing at this site. Eight of these products were developed at Tampa, FL and only one was transferred. Six products with active commercial manufacturing for US and international markets.

  • 9 products approved from this site
  • 6 currently in active commercial manufacturing
  • Present in US and international markets
  • Includes bottle and blister commercial packaging
  • Includes capsule, tablet and DPI products

Highly skilled and dedicated team. Proven expertise from pre-clinical to commercial for oral solid and inhaled drug products. Our development experts work hand in hand with our manufacturing team to ensure consistent, reliable commercial supply. 

Challenge

How we solve it

  Need to get to clinic fast  First-in-human quick-to-clinic option: cGMP drug product from drug substance with minimal formulation development.      
  Too many vendors across the lifecycle  One site: development, clinical manufacturing, QC, packaging, storage, regulatory.
  DEA-scheduled compound complexity  DEA Schedule I to V analytical and manufacturing licenses in place.
  Highly potent compound handling  Dedicated HPAPI containment for oral solid dosage and DPI manufacturing.
  Regulatory submission risk   5 FDA inspections. 12 non-US market audits.
  Current CDMO has no proven path to commercial  9 approvals. 6 products on market today. From this site. 

CDMO Capabilities

Full-lifecycle oral solid dosage and DPI drug product services, with format-specific development and manufacturing capabilities under a shared quality and regulatory framework.

Product Development DEA Schedule I to V – Analytical License

 

PRE-FORMULATION

  • API characterization
  • Excipient compatibility
  • Feasibility studies

FORMULATION DEVELOPMENT

  • Immediate release tablets and capsules
  • Modified release tablets and capsules
  • Micro-dosing and low-dose formulations

ANALYTICAL DEVELOPMENT

  • Method development and validation

 

cGMP Manufacturing | DEA Schedule I to V – Manufacturing License

 

DOSAGE FORMS

  • Immediate release tablets and capsules
  • Modified release tablets and capsules

PRECISION DOSING

  • Micro-dosing and low-dosing PIC
  • Xcelodose® Precision Powder System
  • Harro Hofliger
  • MG2

SPECIAL CAPABILITIES

  • HPAPI high-containment manufacturing
  • Clinical and commercial scale

 

Product Development DEA Schedule I to V – Analytical License

 

PRE-FORMULATION

  • API characterization for inhalation
  • Particle engineering
  • Feasibility studies

FORMULATION DEVELOPMENT

  • DPI formulation development
  • Inhalation performance optimization

ANALYTICAL DEVELOPMENT

  • Method development and validation
  • Inhalation and DPI analytical services

 

cGMP Manufacturing | DEA Schedule I to V – Manufacturing License

 

DPI MANUFACTURING

  • Zephyr® DPI capsule manufacturing
  • Clinical and commercial scale

PRECISION DOSING

  • Micro-dosing and low-dosing PIC
  • Xcelodose® Precision Powder System
  • Harro Hofliger

SPECIAL CAPABILITIES

  • HPAPI high-containment manufacturing
  • Gerteis Roller Compactor
  • Bi-layer tablets
  • Pancoating
  • Fette Tableting Equipment
  • Tablet in Capsule technology
  • Low Humidity

 

 

Shared services across oral solid dosage and DPI

 

The following capabilities serve both product formats under the same quality system, team, and DEA licensing framework.

 

cGMP Packaging | DEA Schedule I to V – Manufacturing License

 

 

PRIMARY PACKAGING

  • Manual and automated bottling
  • Blistering: thermoform and coldform

SECONDARY PACKAGING

  • Secondary packaging
  • Kitting and serialization

 

Quality Control Testing and Stability | DEA Schedule I to V – Analytical License

 

ANALYTICAL QC

  • QC release testing
  • In-process testing
  • Raw materials laboratory

STABILITY

  • Multiple ICH stability storage conditions
  • Long-term, accelerated, and stress testing

MICROBIOLOGY

  • Environmental monitoring (EM)
  • Raw material testing
  • Product microbiology

 

Warehouse Storage and Logistics | cGMP

 

RAW MATERIALS

  • GMP dispensing of raw materials for MFG and PKG

PRODUCT STORAGE

  • Clinical product storage

 

Regulatory Affairs | Global submissions support

 

DOCUMENTATION

  • Prepare regulatory documents for filing
  • IND, NDA, ANDA, and MAA support

SUBMISSIONS

  • Support for regulatory submissions
  • Post-approval regulatory support

STRATEGY

  • Guidance on regulatory strategy
  • Inspection readiness

 

Need to get to clinic fast?

Ask us about our first-in-human quick-to-clinic option for early-phase oral solid dosage and DPI programs. Contact us here.

Drug Product Lifecycle Coverage

Engage our CDMO solutions team at any stage in the lifecycle of a product, with full continuity of quality assurance, project management, and regulatory compliance throughout.

Familiarization R&D

  • Process development
  • Analytical development
  • Scale-up
  • Pilot testing

Engineering cGMP

  • Process optimization
  • Product characterization
  • Scale-up
  • Specifications
  • Impurity profiling

cGMP Manufacture

  • Process characterization
  • Process validation
  • Clinical and commercial scale-up

Commercial Manufacturing

  • Technology transfer
  • Post-market scale-up and optimization
  • Regulatory Affairs support

Therapeutic Areas

Our CDMO solutions support oral solid dosage and DPI programs across:

  • Oncology and HPAPIs
  • Respiratory and inhalation
  • CNS
  • Metabolic and chronic diseases
  • Oral peptides
  • Rare diseases

Regulatory Credentials

5 successful FDA inspections and 12 regulatory audits in the past 8 years, across five major health authorities. Quality assurance systems built for global regulatory compliance from day one.

FDA

United States

MHRA

United Kingdom

ANVISA

Brazil

Ministry of Health

Turkey

Ministry of Health

Russia

Part of the global pharmaceutical solutions network

Need early-stage formulation development? Explore Innovaform® Accelerator, our European center for custom capsule design and DPI formulation development, with a structured pathway for cGMP transfer to our Tampa CDMO site.

Ready to discuss your oral solid dosage or DPI program?

Talk to our CDMO solutions team about first-in-human clinical supply, cGMP manufacturing, packaging, or commercial scale-up. Contact us here.

Contact Us